CJC-1295
GHRH analog with extended half-life through DAC technology, providing sustained pulsatile GH release over days
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been modified with Drug Affinity Complex (DAC) technology to dramatically extend its half-life. While natural GHRH has a half-life of just minutes, CJC-1295 with DAC binds to serum albumin, extending its activity to approximately 6-8 days per injection.
This extended half-life fundamentally changes the pharmacology: rather than producing acute GH pulses, CJC-1295 elevates the baseline "trough" levels of GH and IGF-1 over time, resulting in sustained anabolic and lipolytic effects. This makes weekly or twice-monthly dosing practical, in contrast to the multiple-daily-injection schedules required by shorter-acting GHRH analogs.
CJC-1295 is most commonly used in combination with a GH secretagogue such as ipamorelin, which provides the acute GH pulse on top of CJC-1295's elevated baseline—a combination widely considered synergistic and more physiological than either agent alone. It is particularly popular for body composition optimization and recovery in athletes and anti-aging protocols.
Primary Benefits
GHRH analog that stimulates natural growth hormone release, clinically proven to reduce visceral adipose tissue
Potent synthetic GH secretagogue producing stronger GH release than ipamorelin, with notable cardioprotective properties
Oral GH secretagogue and ghrelin receptor agonist with non-peptide structure enabling once-daily oral dosing